Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide-Reference-Cited by-同舟云学术

Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide

Published:2019-01-14 Issue:1 Volume:369 Page:26-36
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Moldovan Loomis Cristina,Dutzar Benjamin,Ojala Ethan W.,Hendrix Lee,Karasek Charlie,Scalley-Kim Michelle,Mulligan Jenny,Fan Pei,Billgren Jens,Rubin Vanessa,Boshaw Heidi,Kwon Gayle,Marzolf Sam,Stewart Erica,Jurchen David,Pederson Susan M.,Perrino McCulloch Lisa,Baker Brian,Cady Roger K.,Latham John A.,Allison Dan,Garcia-Martinez Leon F.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference97 articles.

1. Neuronal PAC 1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine

2. A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization

3. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers

4. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38

5. Tissue Distribution of PACAP as Determined by RIA: Highly Abundant in the Rat Brain and Testes

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Monoclonal Antibody to PACAP for Migraine Prevention;New England Journal of Medicine;2024-09-05

2. Potential treatment targets for migraine: emerging options and future prospects;The Lancet Neurology;2024-03

3. Understanding the Biological Relationship between Migraine and Depression;Biomolecules;2024-01-30

4. Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention;Expert Opinion on Emerging Drugs;2024-01-02

5. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study;The Journal of Headache and Pain;2023-05-25